Oryzon Genomics S.A. (BME:ORY)
Spain flag Spain · Delayed Price · Currency is EUR
2.336
-0.010 (-0.43%)
Nov 16, 2026, 5:35 PM CET

Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of EUR 191.46 million. The enterprise value is 187.57 million.

Market Cap191.46M
Enterprise Value 187.57M

Important Dates

The next estimated earnings date is Saturday, February 27, 2027.

Earnings Date Feb 27, 2027
Ex-Dividend Date n/a

Share Statistics

Oryzon Genomics has 81.96 million shares outstanding. The number of shares has increased by 8.94% in one year.

Current Share Class 81.96M
Shares Outstanding 81.96M
Shares Change (YoY) +8.94%
Shares Change (QoQ) +5.68%
Owned by Insiders (%) 13.17%
Owned by Institutions (%) 2.43%
Float 64.97M

Valuation Ratios

PE Ratio n/a
Forward PE 98.98
PS Ratio n/a
PB Ratio n/a
P/TBV Ratio 1.76
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.60

Current Ratio 1.60
Quick Ratio 1.59
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -18,467.48

Financial Efficiency

Return on equity (ROE) is -2.08%.

Return on Equity (ROE) -2.08%
Return on Assets (ROA) -2.66%
Return on Invested Capital (ROIC) n/a
Return on Capital Employed (ROCE) -4.57%
Weighted Average Cost of Capital (WACC) 6.56%
Revenue Per Employee n/a
Profits Per Employee -86,792
Employee Count46
Asset Turnover 0.11
Inventory Turnover 37.79

Taxes

Income Tax -2.99M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -23.78% in the last 52 weeks. The beta is 0.42, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y) 0.42
52-Week Price Change -23.78%
50-Day Moving Average 2.61
200-Day Moving Average 2.85
Relative Strength Index (RSI) 38.61
Average Volume (20 Days) 306,851

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

Revenue n/a
Gross Profit -282,493
Operating Income -11.23M
Pretax Income -6.99M
Net Income -3.99M
EBITDA -11.12M
EBIT -11.23M
Earnings Per Share (EPS) -0.05
Full Income Statement

Balance Sheet

Cash & Cash Equivalents n/a
Total Debt n/a
Net Cash n/a
Net Cash Per Share n/a
Equity (Book Value) n/a
Book Value Per Share n/a
Working Capital 5.79M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.47 million and capital expenditures -79,728, giving a free cash flow of -4.55 million.

Operating Cash Flow -4.47M
Capital Expenditures -79,728
Depreciation & Amortization 96,244
Net Borrowing -1.22M
Free Cash Flow -4.55M
FCF Per Share -0.06
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -8.94%
Shareholder Yield -8.94%
Earnings Yield -2.09%
FCF Yield -2.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Analyst Forecast

The average price target for Oryzon Genomics is 8.10, which is 246.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target 8.10
Price Target Difference 246.75%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (3Y) n/a
EPS Growth Forecast (3Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1